5-(2-Methoxy-4-(((2-(tetrahydro-2H-pyran-4-yl)ethyl)amino)methyl)phenoxy)pyrazine-2-carboxamide manufacturers
- Bevenopran
-
- $59.00
-
2026-05-11
- CAS:676500-67-7
- Purity: 98.69%
- Supply Ability: 10g
- Bevenopran
-
- $59.00
-
2026-05-11
- CAS:676500-67-7
- Purity: 98.69%
- Supply Ability: 10g
- Bevenopran
-
- $65.00
-
2026-05-05
- CAS:676500-67-7
- Min. Order: 10kg
- Purity: 0.99
- Supply Ability: 20tons
|
| | 5-(2-Methoxy-4-(((2-(tetrahydro-2H-pyran-4-yl)ethyl)amino)methyl)phenoxy)pyrazine-2-carboxamide Basic information |
| Product Name: | 5-(2-Methoxy-4-(((2-(tetrahydro-2H-pyran-4-yl)ethyl)amino)methyl)phenoxy)pyrazine-2-carboxamide | | Synonyms: | 5-[2-methoxy-4-[[2-(oxan-4-yl)ethylamino]methyl]phenoxy]pyrazine-2-carboxamide;2-PYRAZINECARBOXAMIDE, 5-[2-METHOXY-4-[[[2-(TETRAHYDRO-2H-PYRAN-4-YL)ETHYL]AMINO]METHYL]PHENOXY]-;Bevenopran;5-(2-Methoxy-4-(((2-(tetrahydro-2H-pyran-4-yl)ethyl)amino)methyl)phenoxy)pyrazine-2-carboxamide;ADL-5945;CB-5945;Inhibitor,CB 5945,Bevenopran,CB5945,inhibit,Opioid Receptor,ADL 5945,ADL5945;Bevenopran, 10 mM in DMSO | | CAS: | 676500-67-7 | | MF: | C20H26N4O4 | | MW: | 386.44 | | EINECS: | | | Product Categories: | | | Mol File: | 676500-67-7.mol |  |
| | 5-(2-Methoxy-4-(((2-(tetrahydro-2H-pyran-4-yl)ethyl)amino)methyl)phenoxy)pyrazine-2-carboxamide Chemical Properties |
| Melting point | 133 - 136 °C | | Boiling point | 575.0±50.0 °C(Predicted) | | density | 1.204±0.06 g/cm3(Predicted) | | storage temp. | Refrigerator, under inert atmosphere | | solubility | Acetonitrile (Slightly), Chloroform (Slightly) | | pka | 14.06±0.50(Predicted) | | form | Solid | | color | White to Off-White |
| | 5-(2-Methoxy-4-(((2-(tetrahydro-2H-pyran-4-yl)ethyl)amino)methyl)phenoxy)pyrazine-2-carboxamide Usage And Synthesis |
| Uses | Bevenopran, is a peripheral μ-opioid receptor antagonist. | | Definition | ChEBI: Bevenopran is an aromatic ether. | | in vivo | Bevenopran is a peripheral μ-opioid receptor antagonist. Bevenopran is currently under investigation for the treatment of opioid-induced bowel dysfunction (OBD)[1]. Bevenopran tends to increase bowel movement (BM) frequency, especially for 0.1 mg twice daily and 4 mg daily, respectively[1]. | | IC 50 | μ Opioid Receptor/MOR |
| | 5-(2-Methoxy-4-(((2-(tetrahydro-2H-pyran-4-yl)ethyl)amino)methyl)phenoxy)pyrazine-2-carboxamide Preparation Products And Raw materials |
|